Company: PFSA
Filing Date: 2025-05-13
Form Type: S-4/A
Source: 0001213900-25-042224
Chunk: 62

Company: Profusa, Inc.
Filing Date: 2025-05-13
Form: S-4/A
Chunk 62
---
View Common Stock, the NorthView Rights, and the NorthView Warrants were $[•], $[•] and $[•] per security, respectively. Upon consummation of the Business Combination, NorthView’s common stock will be listed on Nasdaq under the symbol “PFSA,” and its warrants will be listed on Nasdaq under the symbol “PFSAW.” The mailing address of NorthView’s principal executive offices is 207 West 25 thSt., 9 thfloor, New York, NY 10001, and its telephone number is (212) 494 -9022. Merger Sub NV Profusa Merger Sub Inc. is a Delaware corporation and a direct wholly owned subsidiary of NorthView. Merger Sub was incorporated on October 4, 2022. Merger Sub was formed solely in contemplation of the Business Combination, has not commenced any operations, has only nominal assets and has no liabilities or contingent liabilities, nor any outstanding commitments other than in connection with the Business Combination. Profusa Profusa is a California corporation incorporated on February 2, 2009. Profusa is a digital health technology company based in Berkeley, CA, that has developed a real time, consumer -friendlyplatform that is designed to measure an individual’s biochemistry, be easy to use, be cost -effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. Profusa currently has two products in development, Lumee Oxygen and Lumee Glucose, both of which rely on implantable hydrogel sensors that are permanently injected into subcutaneous tissue and are subject to FDA regulation as class III medical devices. Lumee Oxygen has received CE mark approval in the European Union but has not yet been approved by the FDA for medical use in the US. Lumee Oxygen is designed to measure dissolved tissue oxygen for up to six months following sensor injection. Initial product uses under development include 2 application for the management of wound care for critical limb ischemia (a condition involving blockage in the arteries of the lower extremities, markedly reducing blood flow) patients in surgical settings, followed by use in ambulatory settings, subject to future regulatory approval. Lumee Glucose is an investigational product development system, as Profusa has yet to receive the regulatory approval necessary for commercialization in any jurisdiction. It is being developed for use to monitor optical signals that represent glucose levels in the interstitial (under and between the skin and blood vessels) fluid